Exosome Therapy: What It Is, How It Works, and What the Evidence Says

Exosome therapy is an experimental regenerative treatment that delivers exosomes, the tiny 30 to 150 nanometer vesicles cells use to pass proteins, lipids and RNA to one another, into a joint, the skin or the bloodstream to influence inflammation and tissue repair. As of 2026 the FDA has not approved any exosome product for any use, and most of the evidence still comes from cell and animal studies plus a small number of early human trials.

Exosomes have moved from research labs into clinic marketing quickly. Some clinics present exosome therapy as the next step beyond stem cells. Researchers and regulators are more cautious and point out that the human science is still young.

Exosome therapy represents a real shift in how regenerative medicine approaches healing. Instead of transplanting whole cells into damaged tissue, it delivers the molecular signals those cells release, the instructions that tell your own cells how to respond. It is a different approach, and it comes with both genuine promise and legitimate questions.

The sections below cover what exosomes are, how the therapy is thought to work, what the research shows for each condition, how it is regulated, what it costs and what to ask a provider.

What Exactly Are Exosomes?

Exosomes are the smallest class of extracellular vesicles, the membrane packages cells release to communicate. They measure 30 to 150 nanometers in diameter. For perspective, a human hair is about 70,000 nanometers wide.

These microscopic packages are not empty. Each exosome carries a cargo of:

• Proteins that can trigger specific cellular responses
• Lipids that affect cell membrane function
• mRNA (messenger RNA) that can instruct recipient cells to produce specific proteins
• microRNA that can turn genes on or off in target cells

When an exosome reaches a target cell, it is taken up or fuses with the cell membrane and releases its cargo inside. This lets the originating cell influence the behavior of cells at a distance by sending a set of molecular instructions (1).

Your body uses exosomes constantly for normal functions like immune regulation, tissue maintenance and wound healing. Exosome therapy concentrates these signaling packages and delivers them where healing is needed, amplifying a process that already occurs naturally.

What are exosomes also called?

Researchers increasingly use the broader term extracellular vesicles, or EVs, and "small EVs" for vesicles in the exosome size range. The International Society for Extracellular Vesicles (ISEV) recommends this wording in its MISEV guidelines because the word exosome strictly means a vesicle made inside the cell's endosomes, which most lab methods cannot confirm. Clinics may also say MSC exosomes, MSC-derived EVs, cell-free therapy or secretome therapy, and some products are sold as conditioned media, which contains exosomes along with other secreted proteins.

Where do therapeutic exosomes come from?

Most exosome products are collected from mesenchymal stem cells (also called mesenchymal stromal cells) grown in culture. The cells usually come from bone marrow, adipose (fat) tissue or birth tissues such as umbilical cord, placenta and amniotic tissue. Manufacturers grow the cells, collect the fluid they release and isolate the vesicles by ultracentrifugation, filtration or similar methods. Products sold as "plant exosomes" for skin care are a different material and should not be confused with human cell derived exosomes.

How Does Exosome Therapy Work?

Exosome therapy works through paracrine signaling, the way cells change the behavior of nearby cells through released messages instead of direct contact. Researchers now think much of the benefit once credited to transplanted stem cells comes from what those cells secrete, which is the rationale for using the secretions alone, according to Phinney and Pittenger (2017) (2).

In the lab, MSC exosomes shift immune cells toward a repair mode. Zhang and colleagues (2018) found that in rats with cartilage defects, exosome treated joints had more regenerative M2 macrophages, fewer inflammatory M1 macrophages and lower levels of the inflammatory signals IL-1 beta and TNF alpha (3). The same study traced faster cartilage cell growth to the exosomal enzyme CD73 and its activation of adenosine signaling.

The main mechanisms researchers describe are:

• Immune modulation: calming overactive immune responses and steering macrophages toward tissue repair.
• Anti-inflammatory signaling: lowering inflammatory cytokines in joints, skin and the nervous system.
• Cell survival and growth: microRNA and proteins that reduce cell death and encourage local cells to multiply.
• Blood vessel support: signals that encourage new small blood vessels in healing tissue.

Exosomes do not become new tissue. Their effect depends on the cells already present in the treated area, which is one reason results can differ from person to person.

How Exosome Therapy Differs from Stem Cell Therapy

Stem cell therapy transplants live cells into the body. Exosome therapy delivers only the signaling molecules those cells produce, without the cells themselves.

Think of it this way: if stem cells are the factory workers, exosomes are the instruction manuals they send out. Exosome therapy skips the workers and delivers the manuals directly.

This difference has several practical implications:

No cell survival issue. One of the biggest challenges with stem cell therapy is keeping transplanted cells alive long enough to do their work. Many transplanted stem cells die within days. Exosomes do not need to survive because they are not alive in the first place, and they deliver their molecular cargo on contact.

Lower immune rejection risk. Exosomes lack many of the surface markers that trigger immune responses to whole cells, so the risk of immune rejection is theoretically lower.

Easier to store and standardize. Exosomes can be freeze dried, stored and shipped more easily than living cells. This makes quality control and dosing more consistent, at least in theory.

Potentially different mechanisms. Stem cells can differentiate into new tissue types. Exosomes cannot. They influence existing cells to behave differently, reducing inflammation, promoting repair or modulating immune responses. Whether this produces equivalent clinical results is still an open question (2).

For a detailed comparison of exosomes with platelet-rich plasma, see our article on exosome therapy vs. PRP. The stem cell therapy treatment guide covers the cell based side of the comparison.

Exosomes, stem cells and PRP compared

What the Research Shows

Exosome therapy research is promising but early. Most studies are preclinical (cell cultures and animal models), with a growing but still limited number of human trials.

Orthopedic and Joint Conditions

This is one of the most active areas of exosome research. Animal studies have shown that exosomes derived from mesenchymal stem cells can:

• Promote cartilage repair in osteoarthritis models
• Reduce joint inflammation
• Slow cartilage degeneration
• Improve functional outcomes after joint injury

Zhang and colleagues, writing in Biomaterials (2018), reported that MSC exosomes repaired critical size osteochondral (cartilage and underlying bone) defects in rats, with faster cell growth, better matrix formation and a repair-oriented immune response in the joint (3).

Human data is still limited. Several small studies and case series have reported improvements in pain and function after exosome injections for osteoarthritis of the knee, though rigorous randomized controlled trials are still needed. People researching options for joint pain will find that PRP and hyaluronic acid injections currently have far more human data.

Neurological Applications

Some of the most exciting, and most preliminary, exosome research involves the brain and nervous system. Exosomes can cross the blood-brain barrier, which most therapeutic molecules cannot. This makes them potential vehicles for delivering treatments to the brain.

Preclinical studies have shown promise in:

• Traumatic brain injury recovery
• Stroke rehabilitation
• Neurodegenerative disease models (Alzheimer's, Parkinson's)
• Spinal cord injury

The mechanism appears to involve exosomes promoting neuroprotection, reducing neuroinflammation and supporting the growth of new neural connections, according to a review by Xiong and colleagues (2017) (4). This area is very early stage, and human trials are just beginning.

Skin and Aesthetic Applications

Exosomes are gaining attention in dermatology and aesthetics for their potential to:

• Accelerate wound healing
• Improve skin texture and reduce fine lines
• Enhance results of procedures like microneedling
• Support hair regrowth

A small clinical study by Kwon and colleagues found that an exosome-rich solution improved skin hydration, elasticity and texture compared with standard treatment alone (5). Several dermatology practices now offer exosome-enhanced facials and hair restoration, though the evidence base is still building. Our posts on exosomes for hair loss and the wider hair loss treatment guide go further into that use.

Immune and Inflammatory Conditions

Exosomes derived from mesenchymal stem cells appear to have strong immunomodulatory properties. Research is exploring their potential in:

• Autoimmune conditions
• Chronic inflammatory diseases
• Organ transplant rejection prevention
• Graft-versus-host disease

The anti-inflammatory effects of MSC-derived exosomes have been demonstrated in numerous preclinical studies. The most cited human report is a single patient: Kordelas and colleagues (2014) described a person with therapy-refractory graft-versus-host disease whose symptoms improved after MSC exosome infusions (6). Several clinical trials are now underway for inflammatory conditions, and registered studies can be searched on ClinicalTrials.gov.

How strong is the evidence for each use?

The evidence for exosome therapy is strongest in animals and weakest in large human trials. The table below summarizes where each area stands, based on the studies listed under References.

A useful companion read is our deeper review of the clinical evidence for exosome therapy.

How Exosome Therapy Is Administered

The delivery method depends on the condition being treated:

Injection (most common for orthopedic use). Exosomes are injected directly into the affected joint, tendon or tissue, often guided by ultrasound for precision. The procedure is similar to a cortisone or PRP injection and typically takes 15 to 30 minutes.

Intravenous infusion. For systemic conditions or neurological applications, exosomes may be delivered via IV. This allows them to circulate throughout the body and reach multiple tissues.

Topical application. For skin and hair applications, exosome products are applied directly to the treatment area, often after microneedling or other procedures that enhance absorption.

Nebulized or inhaled. Some early research is exploring inhaled exosome delivery for lung conditions, though this remains experimental.

A typical treatment plan might involve 1 to 3 sessions spaced several weeks apart, though protocols vary significantly between providers because there are no standardized treatment guidelines yet.

What happens at an exosome therapy appointment?

1. Evaluation: the clinician reviews your history, imaging and prior treatments and should explain whether human data exists for your condition.
2. Product review: a careful provider names the cell source and manufacturer and can show sterility and characterization testing for the lot used.
3. Preparation: the skin is cleaned and numbed for an injection, or an IV line is placed for an infusion.
4. Delivery: the product is injected under ultrasound guidance, infused or applied after microneedling.
5. Aftercare and follow-up: most people go home the same day, and a follow-up visit checks pain, function or skin response over the following weeks.

The Regulatory Reality

This is where things get complicated, and where you need to pay close attention.

As of 2026, the FDA has not approved any exosome products for clinical use in the United States. In its 2019 public safety notification on exosome products, the agency reported serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes, and it has issued warning letters to companies marketing exosome products with disease treatment claims (7).

The FDA regulates exosomes used to treat diseases and conditions as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. That means a product needs premarket review, usually through an Investigational New Drug application for trials and a Biologics License Application for approval. Exosome products do not qualify for the lighter rules that apply to some minimally manipulated human tissue (HCT/Ps), although some clinics claim otherwise.

The FDA did approve its first mesenchymal stromal cell therapy in December 2024, for steroid-refractory acute graft-versus-host disease in children. That approval covers a specific living cell product for one narrow use and does not extend to exosomes.

The current gap between marketing and approval means:

1. There is no FDA-approved, quality-controlled exosome product available in the US
2. Clinics offering exosome therapy are operating in a regulatory gray area
3. The quality, purity and actual contents of available exosome products vary enormously
4. Claims about what exosome therapy can treat are largely unsupported by the level of evidence the FDA requires

This regulatory gap creates real risk for patients. Without standardized products, you cannot be sure what you are actually receiving. Different products may contain different concentrations of exosomes, different cargo profiles or potentially harmful contaminants. For the wider picture on cell based products, see which stem cell treatments the FDA has approved.

Safety Considerations

Based on available data, exosome therapy appears to have a favorable safety profile when quality-controlled products are used properly. The most commonly reported side effects are:

• Mild pain or swelling at the injection site
• Temporary inflammation
• Fatigue for 1 to 2 days after treatment

Serious adverse events have been rare in published studies but have occurred with unregulated products. The Nebraska cases described in the FDA's 2019 notification involved products sold outside the agency's review process.

The biggest safety concern is not the exosomes themselves but the lack of quality control in the current market. Patients receiving well-characterized exosome products in clinical trials have experienced very few adverse effects. The risks increase substantially with products of unknown or unverified quality, a point the ISEV position paper by Lener and colleagues (2015) makes about moving vesicle therapies into trials (8).

Who should be cautious about exosome therapy?

Clinicians commonly advise extra caution for people with an active infection, a current or recent cancer, pregnancy or breastfeeding, or a bleeding disorder or blood thinner use before an injection. The cancer caution is partly theoretical: exosomes carry growth and blood vessel signals, and researchers have not ruled out effects on existing tumors. Anyone with an autoimmune disease or a transplant should involve the specialist who manages that condition.

What Exosome Therapy Costs

Exosome therapy is not cheap, and it is not covered by insurance. Prices are set by each clinic and vary by product, dose and region; commonly quoted ranges are:

• Joint injections: $3,000 to $8,000 per treatment
• IV infusion: $5,000 to $15,000+ depending on the condition and protocol
• Skin and aesthetic treatments: $500 to $3,000 per session
• Hair restoration: $2,000 to $6,000 per treatment

These prices reflect the cost of the exosome products themselves (which are expensive to produce and source), the clinical expertise involved, and the market dynamics of a treatment with high demand and limited supply. Because there is no approved product and no billing code for exosome therapy, health insurance and Medicare do not pay for it, and health savings account eligibility depends on your plan.

Who Offers Exosome Therapy?

Exosome injections for joints are usually offered by orthopedic surgeons, sports medicine physicians, physiatrists (physical medicine and rehabilitation doctors) and interventional pain specialists, often in the same practices that offer PRP and stem cell injections. Skin and hair treatments are offered by dermatologists, plastic surgeons and medical spas, and IV exosome infusions are offered mostly by integrative and regenerative medicine clinics.

Regenerated.com lists clinics that offer regenerative treatments, including exosomes, in the national stem cell therapy clinic directory and the directory of PRP providers. Listing order is not paid ranking, Featured slots are labeled and capped, Verified means a clinic completed credential checks rather than paying for placement, and the directory is free for patients. Inclusion is not an endorsement, and the guide to Featured, Verified and organic listings explains each label. Before booking, read our exosome therapy treatment overview and bring the questions below.

Making an Informed Decision

If you are considering exosome therapy, this practical framework helps you compare providers.

Questions to Ask Any Provider

1. Where do your exosomes come from? They should be able to tell you the cell source (usually mesenchymal stem cells from bone marrow, adipose tissue or birth tissue), the manufacturer, and whether the products have been tested for sterility and potency.
2. What quality testing has been done? Look for providers who use products tested for exosome characterization (particle count and size), sterility, endotoxin levels and mycoplasma.
3. What evidence supports this treatment for my condition? A responsible provider should be honest about the evidence level, distinguishing between conditions where human data exists and those where the evidence is still preclinical.
4. What are the realistic expectations for outcomes? Be wary of providers who promise dramatic results or describe exosomes as a permanent fix for a disease.
5. What happens if it does not work? Good providers have a plan for assessing response and adjusting treatment. Witwer and colleagues (2019) set out the identity and potency tests a well characterized MSC vesicle product should have (9).

Red Flags

• Claims that exosome therapy eliminates or permanently fixes specific diseases
• No discussion of the regulatory status or limitations of the evidence
• Pressure to commit to expensive treatment packages upfront
• Unable or unwilling to discuss the source and testing of their exosome products
• Marketing that focuses on testimonials rather than clinical evidence

Green Flags

• Transparent about the evidence level (promising but early)
• Can explain exactly where their products come from and how they are tested
• Performs a thorough medical evaluation before recommending treatment
• Discusses alternative treatments such as PRP, prolotherapy and physical therapy and helps you compare options
• Tracks and shares their own outcome data

The Bottom Line

Exosome therapy sits at the intersection of genuine scientific innovation and premature commercial hype. The underlying science is sound: cells communicate through exosomes, and delivering concentrated exosomes to damaged tissue can influence healing in animal models. Preclinical evidence is strong across multiple conditions.

The human evidence is still limited, the regulatory framework is incomplete, and the quality of commercially available products varies. For patients with conditions that have not responded to established treatments, exosome therapy may be worth exploring, with eyes open about the current limitations and a focus on providers who document their products.

The next decade will likely bring FDA-approved exosome products, standardized treatment protocols and much clearer answers about who benefits most. Until then, informed caution is the smartest approach (10).

For the complete picture on exosome therapy, visit our exosome therapy pillar page.

Frequently asked questions

Is exosome therapy FDA approved?

No. The FDA states that there are currently no FDA-approved exosome products in the United States, and it regulates exosomes used to treat disease as drugs and biological products that require premarket review. Clinics that offer exosome injections, infusions or facials today are using unapproved products outside that review process. Legitimate access to approved-pathway products is through registered clinical trials, which you can search on ClinicalTrials.gov.

What is exosome therapy used for?

Exosome therapy is most often marketed for knee osteoarthritis and other joint injuries, skin rejuvenation, hair loss and inflammatory or autoimmune conditions, with neurological uses such as traumatic brain injury and stroke still at the research stage. For most of these uses the supporting data comes from cell and animal studies and small human reports. Larger randomized trials are still needed before any of these uses can be called established.

How long does exosome therapy take to work?

There is no established timeline, because no standardized protocol or large trial defines one. Clinics commonly tell patients to expect any change over several weeks to a few months, and plans often involve 1 to 3 sessions spaced several weeks apart. Ask the provider how and when they will measure your response, such as pain and function scores for a joint or photos for skin, so you can judge the result.

Is exosome therapy better than stem cell therapy or PRP?

There is no head-to-head evidence that exosome therapy works better than stem cell therapy or PRP. Exosomes avoid the problem of transplanted cells dying and carry a lower theoretical rejection risk, but they depend on donor products of variable quality. PRP uses your own blood and has the largest body of human trials of the three for knee osteoarthritis, which is why many clinicians try it first.

What are the side effects of exosome therapy?

The side effects reported most often are mild pain or swelling at the injection site, temporary inflammation and fatigue for 1 to 2 days. Serious adverse events have been rare in published studies but have occurred with unregulated products, including the cases in Nebraska that prompted the FDA's 2019 safety notification. The source, sterility and testing of the product are the main factors that change the risk.

Does insurance cover exosome therapy?

No. Because no exosome product is FDA approved, health insurance and Medicare do not cover exosome therapy, and patients pay cash. Commonly quoted ranges run from $500 to $3,000 per aesthetic session up to $5,000 to $15,000 or more for an IV infusion, with joint injections in between. Ask for a written quote that names the product, the dose and every follow-up visit included.

Sources

1. Kalluri R, LeBleu VS. (2020). The biology, function, and biomedical applications of exosomes. Science, 367(6478), eaau6977. doi:10.1126/science.aau6977 (PubMed) ↩
2. Phinney DG, Pittenger MF. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35(4), 851-858. doi:10.1002/stem.2575 ↩
3. Zhang S, et al. (2018). MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials, 156, 16-27. doi:10.1016/j.biomaterials.2017.11.028 (PubMed) ↩
4. Xiong Y, et al. (2017). Emerging potential of exosomes for treatment of traumatic brain injury. Neural Regeneration Research, 12(1), 19-22. doi:10.4103/1673-5374.198966 ↩
5. Kwon HH, et al. (2020). Stem cell-derived exosome-rich solution for skin rejuvenation. Journal of Cosmetic Dermatology, 19(8), 2053-2061. doi:10.1111/jocd.13494 ↩
6. Kordelas L, et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28(4), 970-973. doi:10.1038/leu.2014.41 (PubMed) ↩
7. U.S. Food and Drug Administration. (2019). Public safety notification on exosome products. FDA.gov ↩
8. Lener T, et al. (2015). Applying extracellular vesicles based therapeutics in clinical trials: an ISEV position paper. Journal of Extracellular Vesicles, 4, 30087. doi:10.3402/jev.v4.30087 ↩
9. Witwer KW, et al. (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 8(1), 1609206. doi:10.1080/20013078.2019.1609206 (PubMed)
10. Wiklander OPB, et al. (2019). Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 11(492), eaav8521. doi:10.1126/scitranslmed.aav8521 ↩

Related Reading

• Exosome Therapy vs PRP: Comparing Regenerative Options
• Complete Guide to Exosome Therapy
• Stem Cell Therapy: What You Need to Know
• PRP Therapy: What You Need to Know
• Regenerative Medicine for Longevity